Drug
Crizotinib clinical trials
Also written PF-02341066, Xalkori and PF-2341066.
- studies test it
- 84
- open now
- 10
- in phase 3
- 7
- first study started
- 2006
Keep track of what changes. Save the Crizotinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Xalkori
- 35
Development codes
Studies by the year they started
84 studies that test it; most in 2015 (12)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2009 | 3 |
| 2010 | 10 |
| 2011 | 5 |
| 2012 | 8 |
| 2013 | 7 |
| 2014 | 10 |
| 2015 | 12 |
| 2016 | 6 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 34
- Phase 2
- 42
- Phase 3
- 7
- Phase 4
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 33 · Other 51
Pfizer (29) · National Cancer Institute (NCI) (11) · M.D. Anderson Cancer Center (4) · Hunan Province Tumor Hospital (3) · IDEAYA Biosciences (2) · Samsung Medical Center (2) · ECOG-ACRIN Cancer Research Group (1) · Hoffmann-La Roche (1)
Often tested with
Tested in the same studies.
Erlotinib (7) · Dasatinib (6) · Palbociclib (6) · Sunitinib (6) · Alectinib (6) · Axitinib (6) · Nivolumab (5) · Trastuzumab (5)
Studies
Open first, then newest update. How each study uses Crizotinib is read from its arms, and is right about nine times in ten.
Testing it · 84
- Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom TrialRecruitingPhase 1M.D. Anderson Cancer CenterNCT04693468Written as Crizotinib
- Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaRecruitingPhase 3IDEAYA BiosciencesNCT07804186Written as Crizotinib (Xalkori)
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as Crizotinib
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Written as Crizotinib
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04423185Written as Crizotinib 250 MG
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruitingPhase 2Hunan Province Tumor HospitalNCT04322890Written as Crizotinib 250 MG
- ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell CarcinomaRecruitingPhase 2Hunan Province Tumor HospitalNCT05014464Written as Crizotinib
- Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLCRecruitingPhase 2Hunan Province Tumor HospitalNCT04322578Written as Crizotinib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Crizotinib
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingPhase 2Oslo University HospitalNCT05725200Written as Crizotinib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Crizotinib
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruitingNot applicableNational Cancer Institute (NCI)NCT02194738Written as Crizotinib
- Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06360575Written as Crizotinib
- A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive CancerCompletedPhase 3Hoffmann-La RocheNCT03194893Written as Crizotinib
- Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439253Written as Crizotinib
- Study of Crizotinib for ROS1 and MET Activated Lung CancerCompletedPhase 2University Health Network, TorontoNCT04084717Written as Crizotinib
- Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439266Written as Crizotinib
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedPhase 2University of BirminghamNCT02664935Written as Crizotinib
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerTerminatedPhase 2National Cancer Institute (NCI)NCT03737994Written as Crizotinib
- Crizotinib Continuation Clinical StudyActive, not recruitingPhase 4PfizerNCT05160922Written as crizotinib
See all 84 studies that test Crizotinib →
Given in every arm · 9 — Crizotinib is usual care beside what is tested
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsRecruitingPhase 1/2IDEAYA BiosciencesNCT03947385Written as Crizotinib
- Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid TumoursCompletedPhase 2Royal Marsden NHS Foundation TrustNCT03620643Written as Crizotinib Oral Capsule [Xalkori]
- Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical TrialsCompletedNot applicablePfizerNCT00828919Written as crizotinib
- Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaCompletedPhase 1Children's Oncology GroupNCT01606878Written as Crizotinib
- MEK and MET Inhibition in Colorectal CancerCompletedPhase 1University of OxfordNCT02510001Written as PF-02341066
- A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1/2Bristol-Myers SquibbNCT02574078Written as Crizotinib
- Lorlatinib Combinations in Lung CancerStatus unknownPhase 1/2Massachusetts General HospitalNCT04292119Written as Crizotinib
- Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder CarcinomaStatus unknownPhase 2Shanghai Jiao Tong University School of MedicineNCT02836847Written as Crizotinib
- A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.CompletedPhase 1PfizerNCT03137134Written as Crizotinib
As the comparator · 15 — what is tested is compared with Crizotinib
- A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 3Guangzhou JOYO Pharma Co., LtdNCT07816380Written as Crizotinib Capsules
- A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsRecruitingPhase 3Nuvation Bio Inc.NCT06564324Written as Crizotinib
- A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCNot yet recruitingPhase 3Shouyao Holdings (Beijing) Co. LTDNCT06254599Written as Crizotinib Capsules
- A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus CrizotinibNot yet recruitingPhase 3Xuanzhu Biopharmaceutical Co., Ltd.NCT05204628Written as Crizotinib
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)Active, not recruitingPhase 3Bristol-Myers SquibbNCT06140836Written as Crizotinib
- A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesActive, not recruitingPhase 3Hoffmann-La RocheNCT04603807Written as Crizotinib
- A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 3Hoffmann-La RocheNCT02838420Written as Crizotinib
- A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer ParticipantsCompletedPhase 3Hoffmann-La RocheNCT02075840Written as Crizotinib
- A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCActive, not recruitingPhase 3PfizerNCT03052608Written as Crizotinib
- eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingPhase 3Xcovery Holdings, Inc.NCT02767804Written as crizotinib
- TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 3Shenzhen TargetRx, Inc.NCT06082635Written as Crizotinib
- A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular AlterationsCompletedPhase 1/2PfizerNCT01970865Written as Crizotinib
- Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT04632758Written as crizotinib
- ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsCompletedPhase 3Ariad PharmaceuticalsNCT02737501Written as Crizotinib
- Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)Status unknownPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04009317Written as Crizotinib
Codes
What other systems call Crizotinib · ClinicalTrials.gg INT006744
- MeSH (NLM) D000077547CrizotinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 53AH36668SCRIZOTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1148495Confirmed FDA, Wikidata
- Wikidata Q5186964crizotinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74061CrizotinibOne source FDA
- DrugBank DB08865One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077547 | Crizotinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 53AH36668S | CRIZOTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1148495 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5186964 | crizotinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74061 | Crizotinib | One source FDA |
| DrugBank | DB08865 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.